All News

Rykindo is a bi-weekly long-acting risperidone injection to treat patients with schizophrenia and bipolar 1 in adults.

Your weekly roundup of the latest news from Drug Topics®.

This National Pharmacist Day, take the time to reflect on how pharmacists have stepped up during the pandemic.

Pharmacists can play an important role in patients’ wellness journeys.

Clarivate analysts have identified the treatments they forecast could deliver annual sales of more than $1 billion within 5 years. These include therapies for rare diseases, as well as HIV, Parkinson’s disease, Crohn’s disease, alopecia, and cancer.

Custom is one of the growing number of companies focusing on adherence. It changed its name from Pack4U last year.

Approval followed resubmission of data from the phase 3 CONFIRM trial to the agency.

Your weekly roundup of the latest news from Drug Topics®.

List prices of 450 medications have increased 5% overall at the beginning of 2023. More price hikes are expected.

Your weekly roundup of the latest news from Drug Topics®.

Your weekly roundup of the latest news from Drug Topics®.

With supply chain issues impacting many industries, drug shortages have occurred. How does the FDA address them?

Relyvrio is intended to slow the disease progression of amyotrophic lateral sclerosis.

A group of pharmacists rose to the occasion to help a man having a medical emergency aboard a recent United flight bound for Newark, New Jersey.

Your weekly roundup of the latest news from Drug Topics®.

Mark Cuban’s Cost Plus Drugs business has entered into agreements with Capital Blue Cross and Rightway.

Seven of the 10 top selling drugs with high price increases lack the clinical evidence to justify those increases.

Pharmacists can optimize medication adherence and serve as an additional touchpoint for patients during treatment.

Short-term manufacturing problems are happening as the demand for Adderall and other stimulant medications for ADHD have increased. Data from Arrive Health show a marked increase in ADHD medication prescriptions for people in their 30s.

Your weekly roundup of the latest news from Drug Topics®.

Lecanemab is an investigational anti-amyloid beta antibody to treat mild cognitive impairment due to Alzheimer’s disease. It is currently under review by the FDA and a decision is expected by January 6, 2023.

The treatment is approved for preventing recurrent Clostridioides difficile infections.

Privacy rules to improve coordination of care, avoid discrimination in treatment.

Take a look back at our most popular news from November 2022.

The fight to put the consumer first in health care remains as many Americans feel the industry is still putting the mighty dollar ahead of patients.

Your weekly roundup of the latest news from Drug Topics®.

Take a look back at our most popular health system coverage for 2022.

Take a look back at our most popular COVID-19 coverage for 2022.